The Non-Malignant Channel is supported with funding from Agios (Gold).
The Sickle Cell Disease Channel is supported with funding from Agios (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | The evolving treatment landscape of SCD
Clark Brown, MD, PhD, Aflac Cancer & Blood Disorders Center, Atlanta, GA, discusses advances in the field of sickle cell disease (SCD), discussing the mechanism of action of drugs such as voxelotor and GBT021601, and highlighting the promise of gene therapy and combination therapies. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Consultancy: Global Blood Therapeutics, Imara, Novartis, Novo Nordisk; Research support: Global Blood Therapeutics, Forma Therapeutics, Imara, Novartis, Pfizer
